Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
Highlights in gynecologic cancer from ESMO 2023
Manage episode 385528189 series 2424442
The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX).
Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.
The post Highlights in gynecologic cancer from ESMO 2023 appeared first on VJOncology.
177 tập
Manage episode 385528189 series 2424442
The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX).
Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.
The post Highlights in gynecologic cancer from ESMO 2023 appeared first on VJOncology.
177 tập
Tất cả các tập
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.